Connect with us

Technology

Tecsys Reports Financial Results for the Third Quarter of Fiscal 2025

Published

on

Record Revenue Quarter Led by SaaS

MONTREAL, March 5, 2025 /CNW/ — Tecsys Inc. (TSX: TCS), an industry-leading supply chain management SaaS company, today announced its results for the third quarter of fiscal 2025, ended January 31, 2025. All dollar amounts are expressed in Canadian currency and are prepared in accordance with International Financial Reporting Standards (IFRS).

“This quarter, we achieved record revenue driven by strong growth in SaaS.  We’re seeing diversified activity across key sectors, from major health systems to healthcare 3PLs as well as industrial distributors.  Our pharmacy supply chain solutions continue to drive strong market activity.” said Peter Brereton, president and CEO of Tecsys.

Mark Bentler, chief financial officer of Tecsys, added, “We are experiencing strong momentum in our SaaS business, coupled with increasing profitability. We’re pleased to see Adjusted EBITDA scaling effectively, up 33% year-to-date.”

Third quarter highlights:

SaaS revenue increased by 22% to $17.3 million, up from $14.2 million in Q3 2024.SaaS subscription bookingsi (measured on an ARRi basis) were $4.0 million compared to $4.9 million in the third quarter of fiscal 2024.SaaS Remaining Performance Obligation (RPOi) increased by 34% to $210.2 million at January 31, 2025, up from $157.2 million at the same time last year.Total revenue increased to a record $45.2 million compared to $43.8 million in Q3 2024.Net profit was $1.2 million or $0.08 per share on a fully diluted basis in Q3 2025, compared to a net profit of $0.8 million or $0.05 per share for the same period in fiscal 2024.Adjusted EBITDAii was $3.5 million compared to $2.6 million reported in Q3 last year.In the third quarter of fiscal 2025, Tecsys acquired 38,200 of its outstanding common shares for approximately $1.7 million as part of its ongoing Normal Course Issuer Bid, compared to 50,400 shares acquired in the same period last year for approximately $1.5 million.

Year-to-date performance for first nine months of fiscal 2025

SaaS revenue increased by 29% to $48.7 million, up from $37.7 million in the same period of fiscal 2024.SaaS subscription bookingsi (measured on an ARRi basis) increased by 3% to $10.8 million, compared to $10.5 million in the same period of fiscal 2024.Total revenue increased to $129.9 million compared to $127.3 million in the same period of fiscal 2024.Net profit was $2.7 million ($0.19 per basic share or $0.18 per fully diluted share) in the first nine months of fiscal 2025, compared to a net profit of $1.6 million ($0.11 per basic and fully diluted share) for the same period in fiscal 2024.Adjusted EBITDAii was $9.1 million compared to $6.8 million reported in the same period of fiscal 2024.In the first nine months of fiscal 2025, Tecsys acquired 149,400 of its outstanding common shares for approximately $6.0 million as part of its ongoing Normal Course Issuer Bid, compared to 76,200 shares acquired in the same period last year for approximately $2.2 million.

Financial guidance:

Tecsys is maintaining its FY25 guidance for SaaS revenue growth of 30-32% and Adjusted EBITDA margins of 8-9% for FY25 and 10-11% for FY26. We saw strong Q3 Professional Services bookings and year-over-year growth in SaaS bookings; however, the timing of these bookings is expected to result in full-year AEBITDA margins and SaaS revenue being at the lower end of the guidance range.

Overall, based on actual third quarter hardware shipments and visibility into overall fourth quarter revenue, the Company is raising its fiscal 2025 total revenue growth guidance from flat to 1-3% growth and will provide fiscal 2026 guidance with its Q4 and full-year fiscal 2025 earnings release.

On March 5, 2025, the Company declared a quarterly dividend of $0.085 per share to be paid on April 16, 2025 to shareholders of record on March 26, 2025.

Pursuant to the Canadian Income Tax Act, dividends paid by the Company to Canadian residents are considered to be “eligible” dividends.

i See Key Performance Indicators in Management’s Discussion and Analysis of the Q3 2025 Financial Statements.

ii See Non-IFRS Performance Measures in Management’s Discussion and Analysis of the Q3 2025 Financial Statements

Q3 2025 Financial Results Conference Call
Date: March 6, 2025
Time: 8:30 a.m. ET
Phone number: 800-836-8184 or 646-357-8785
The call can be replayed until March 13, 2025, by calling:
888-660-6345 or 646-517-4150 (access code: 14330#)

About Tecsys

Tecsys is a global provider of advanced supply chain solutions. With a commitment to innovation and customer success, the company equips organizations with the essential software, technology and expertise needed for operational excellence and competitive advantage. Its cloud solutions serve a diverse range of industries, including healthcare, distribution and converging commerce, across multiple complex, regulated and high-volume markets. Built on the Itopia® low-code application platform, Tecsys’ offerings include enterprise resource planning, warehouse management, consolidated service management, distribution and transportation management, supply management at the point of use and order management solutions. Tecsys provides critical data insights and control across the supply chain, ensuring that organizations are agile, responsive and scalable.

Tecsys is publicly traded on the Toronto Stock Exchange under the ticker symbol TCS. For more about Tecsys and its solutions, please visit www.tecsys.com.

Forward Looking Statements

The statements in this news release relating to matters that are not historical fact are forward-looking statements that are based on management’s beliefs and assumptions. Such statements are not guarantees of future performance and are subject to a number of uncertainties, including but not limited to future economic conditions, the markets that Tecsys Inc. serves, the actions of competitors, major new technological trends, and other factors beyond the control of Tecsys Inc., which could cause actual results to differ materially from such statements. More information about the risks and uncertainties associated with Tecsys Inc.’s business can be found in the MD&A section of the Company’s annual report and the most recently filed annual information form. These documents have been filed with the Canadian securities commissions and are available on our website (www.tecsys.com) and on SEDAR+ (www.sedarplus.ca).

Copyright © Tecsys Inc. 2025. All names, trademarks, products, and services mentioned are registered or unregistered trademarks of their respective owners.

Non-IFRS Measures

Reconciliation of EBITDA and Adjusted EBITDA

EBITDA is calculated as earnings before interest expense, interest income, income taxes, depreciation and amortization. Adjusted EBITDA is calculated as EBITDA before stock-based compensation and restructuring costs. The exclusion of interest expense, interest income, income taxes and restructuring costs eliminates the impact on earnings derived from non-operational activities and non-recurring items, and the exclusion of depreciation, amortization and stock-based compensation eliminates the non-cash impact of these items.

The Company believes that these measures are useful measures of financial performance without the variation caused by the impacts of the items described above and that could potentially distort the analysis of trends in our operating performance. In addition, they are commonly used by investors and analysts to measure a company’s performance, its ability to service debt and to meet other payment obligations, or as a common valuation measurement. Excluding these items does not imply that they are necessarily non-recurring. Management believes these non-IFRS financial measures, in addition to conventional measures prepared in accordance with IFRS, enable investors to evaluate the Company’s operating results, underlying performance and future prospects in a manner similar to management. Although EBITDA and Adjusted EBITDA are frequently used by securities analysts, lenders and others in their evaluation of companies, they have limitations as an analytical tool, and should not be considered in isolation, or as a substitute for analysis of the Company’s results as reported under IFRS.

The reconciliation of EBITDA and Adjusted EBITDA to the most directly comparable IFRS measure is provided below. 

Three months

ended January 31,

Nine months

ended January 31,

Trailing 12 months

ended January 31,

(in thousands of CAD)

2025

2024

2025

2024

2025

2024

Net profit for the period

$

1,193

$

759

$

2,749

$

1,590

$

3,008

$

2,036

Adjustments for:

Depreciation of property and equipment and right-of-use assets

376

355

1,124

1,116

1,485

1,556

Amortization of deferred development costs

190

147

585

436

732

581

Amortization of other intangible assets

322

356

984

1,146

1,331

1,548

Interest expense

18

45

67

136

94

153

Interest income

(150)

(260)

(530)

(782)

(763)

(993)

Income taxes

811

644

1,674

1,422

893

2,177

EBITDA

$

2,760

$

2,046

$

6,653

$

5,064

$

6,780

$

7,058

Adjustments for:

Stock based compensation

775

594

2,415

1,770

2,946

2,225

Restructuring costs

2,122

Adjusted EBITDAii

$

3,535

$

2,640

$

9,068

$

6,834

$

11,848

$

9,283

 

Condensed Interim Consolidated Statements of Financial Position
(Unaudited)

(In thousands of Canadian dollars)

January 31, 2025

April 30, 2024

Assets

Current assets

Cash and cash equivalents

$

20,970

$

18,856

Short-term investments

11,614

16,713

Accounts receivable

21,563

22,090

Work in progress

7,060

4,248

Other receivables

189

134

Tax credits

5,365

6,422

Inventory

1,937

1,359

Prepaid expenses and other

9,756

9,143

Total current assets

78,454

78,965

Non-current assets

Other long-term receivables and assets

640

421

Tax credits

6,757

4,737

Property and equipment

1,068

1,372

Right-of-use assets

934

1,251

Contract acquisition costs

4,610

4,478

Deferred development costs

3,430

2,683

Other intangible assets

6,833

7,703

Goodwill

17,517

17,363

Deferred tax assets

9,073

9,073

Total non-current assets

50,862

49,081

Total assets

$

129,316

$

128,046

Liabilities

Current liabilities

Accounts payable and accrued liabilities

24,677

20,030

Deferred revenue

38,684

36,211

Lease obligations

732

812

Total current liabilities

64,093

57,053

Non-current liabilities

Other long-term accrued liabilities

3,886

496

Deferred tax liabilities

552

826

Lease obligations

783

1,302

Total non-current liabilities

5,221

2,624

Total liabilities

$

69,314

$

59,677

Equity

Share capital

$

53,788

$

52,256

Contributed surplus

5,877

9,417

Retained earnings

7,251

8,121

Accumulated other comprehensive loss

(6,914)

(1,425)

Total equity attributable to the owners of the Company

60,002

68,369

Total liabilities and equity

$

129,316

$

128,046

 

Condensed Interim Consolidated Statements of Income and Comprehensive (Loss) Income
(Unaudited)

(In thousands of Canadian dollars, except per share data)

Three Months Ended

January 31,

Nine Months Ended

January 31,

2025

2024

2025

2024

Revenue:

SaaS

$

17,252

$

14,160

$

48,696

$

37,727

Maintenance and Support

8,142

8,620

24,560

25,817

Professional Services

13,920

13,021

41,452

40,798

License

212

396

1,517

1,104

Hardware

5,655

7,626

13,674

21,841

Total revenue

45,181

43,823

129,899

127,287

Cost of revenue

23,907

23,893

68,449

69,512

Gross profit

21,274

19,930

61,450

57,775

Operating expenses:

Sales and marketing

9,053

8,223

26,457

24,539

General and administration

3,096

2,650

9,273

8,580

Research and development, net of tax credits

7,114

7,834

21,650

22,079

Total operating expenses

19,263

18,707

57,380

55,198

Profit from operations

2,011

1,223

4,070

2,577

Other (costs) income

(7)

180

353

435

Profit before income taxes

2,004

1,403

4,423

3,012

Income tax expense

811

644

1,674

1,422

Net profit

$

1,193

$

759

$

2,749

$

1,590

Other comprehensive (loss) income:

Effective portion of changes in fair value on designated revenue hedges

(5,188)

4,101

(5,721)

1,101

Exchange differences on translation of foreign  operations

(90)

(90)

232

(424)

Comprehensive (loss) income

$

(4,085)

$

4,770

$

(2,740)

$

2,267

Basic earnings per common share

$

0.08

$

0.05

$

0.19

$

0.11

Diluted earnings per common share

$

0.08

$

0.05

$

0.18

$

0.11

 

Condensed Interim Consolidated Statements of Cash Flows
(Unaudited)

(In thousands of Canadian dollars)

Three Months Ended

January 31,

Nine Months Ended

January 31,

2025

2024

2025

2024

Cash flows from operating activities:

Net profit

$

1,193

$

759

$

2,749

$

1,590

Adjustments for:

Depreciation of property and equipment and right-of-use-assets

376

355

1,124

1,116

Amortization of deferred development costs

190

147

585

436

Amortization of other intangible assets

322

356

984

1,146

Interest (income) expense and foreign exchange loss

7

(180)

(353)

(435)

Unrealized foreign exchange and other

516

(452)

599

(1,050)

Non-refundable tax credits

(1,008)

(151)

(1,942)

(1,365)

Stock-based compensation

775

594

2,415

1,770

Income taxes

34

78

221

454

Net cash from operating activities excluding changes in non-cash working capital items related to operations

2,405

1,506

6,382

3,662

Accounts receivable

269

(4,175)

571

(1,950)

Work in progress

(2,563)

557

(2,804)

(1,662)

Other receivables and assets

90

184

(346)

136

Tax credits

3,338

3,160

979

841

Inventory

178

213

(576)

(871)

Prepaid expenses

(1,534)

(304)

(571)

(945)

Contract acquisition costs

(251)

(401)

(171)

(261)

Accounts payable and accrued liabilities

3,111

3,890

1,111

597

Deferred revenue

1,764

(2,295)

2,455

327

Changes in non-cash working capital items related to operations

4,402

829

648

(3,788)

Net cash provided by (used in) operating activities

6,807

2,335

7,030

(126)

Cash flows from financing activities:

Payment of lease obligations

(205)

(195)

(607)

(593)

Payment of dividends

(1,251)

(1,177)

(3,619)

(3,385)

Interest paid

(18)

(45)

(67)

(136)

Issuance of common shares on exercise of stock options

971

423

1,568

3,067

Shares repurchased and cancelled

(1,679)

(1,532)

(5,991)

(2,205)

Net cash used in financing activities

(2,182)

(2,526)

(8,716)

(3,252)

Cash flows from investing activities:

Interest received

32

22

59

91

Transfers from short-term investments

18

5,570

40

Acquisitions of property and equipment

(88)

(190)

(497)

(455)

Deferred development costs

(447)

(309)

(1,332)

(809)

Net cash (used in) provided by investing activities

(503)

(459)

3,800

(1,133)

Net increase (decrease) in cash and cash equivalents during the period

4,122

(650)

2,114

(4,511)

Cash and cash equivalents – beginning of period

16,848

17,374

18,856

21,235

Cash and cash equivalents – end of period

$

20,970

$

16,724

$

20,970

$

16,724

 

Condensed Interim Consolidated Statements of Changes in Equity
(Unaudited)

(In thousands of Canadian dollars, except number of shares)

Share capital

Contributed
Surplus

 

Accumulated other
comprehensive
(loss) income

Retained
earnings

Total

Number

Amount

Balance, May 1, 2024

14,840,150

$

52,256

$

9,417

$

(1,425)

$

8,121

$

68,369

Net profit

2,749

2,749

Other comprehensive (loss) income:

Effective portion of changes in fair value on designated revenue hedges

(5,721)

(5,721)

Exchange difference on translation of foreign operations

232

232

Total comprehensive (loss) income

(5,489)

2,749

(2,740)

Shares repurchased and cancelled

(149,400)

(531)

(5,460)

(5,991)

Stock-based Compensation

2,415

2,415

Dividends to equity owners

(3,619)

(3,619)

Share options exercised

53,337

2,063

(495)

1,568

Total transactions with owners of the Company

(96,063)

$

1,532

$

(3,540)

$

$

(3,619)

$

(5,627)

Balance, January 31, 2025

14,744,087

$

53,788

$

5,877

$

(6,914)

$

7,251

$

60,002

Balance, May 1, 2023

14,582,837

$

44,338

15,285

$

(17)

$

10,832

$

70,438

Net profit

1,590

1,590

Other comprehensive income:

Effective portion of changes in fair value on designated revenue hedges

1,101

1,101

Exchange difference on translation of foreign operations

(424)

(424)

Total comprehensive income

677

1,590

2,267

Shares repurchased and cancelled

(76,200)

(248)

(1,957)

(2,205)

Stock-based Compensation

1,770

1,770

Dividends to equity owners

(3,385)

(3,385)

Share options exercised

192,302

3,936

(869)

3,067

Total transactions with owners of the Company

116,102

$

3,688

$

(1,056)

$

$

(3,385)

$

(753)

Balance, January 31, 2024

14,698,939

$

48,026

$

14,229

$

660

$

9,037

$

71,952

 

SOURCE Tecsys Inc.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

HelloNation Article Highlights Sterile Compounding and Medication Safety With Insights From Compounding Pharmacist Expert Laura Temple

Published

on

By

The article explains how sterile compounded medications are prepared to reduce the risk of contamination and support safe, customized treatments.

AZLE, Texas, July 21, 2026 /PRNewswire/ — What does sterile compounding mean for medication safety? HelloNation has published an article explaining how sterile compounding helps pharmacies prepare highly specialized medications while adhering to strict contamination-prevention procedures.

The article features insights from Laura Temple, Compounding Pharmacist Expert and Owner of Laura’s Pharmacy in Azle, Texas. It explains that sterile compounding is a specialized process for preparing medications in carefully controlled environments designed to reduce the risk of contamination. Sterile compounded medications are often used for injections, eye drops, IV medications, and other therapies that require the highest levels of cleanliness and precision.

The HelloNation article explains that sterile compounded medications differ from commercially manufactured drugs because they are prepared individually for a patient’s unique medical needs. Physicians may prescribe compounded prescriptions when a patient requires a customized dosage, a combination medication, or a treatment not commercially available. Because these medications often bypass the body’s natural defenses, medication safety depends on strict preparation standards throughout the compounding process.

The article describes how pharmacies that provide sterile compounding rely on cleanroom environments equipped with filtered-air systems, specialized equipment, and contamination-prevention protocols. Pharmacists and technicians follow detailed gowning, sterilization, and handwashing procedures before handling medication ingredients. These measures are designed to support medication safety by limiting exposure to bacteria, particles, and other contaminants.

According to the article, environmental monitoring also plays a critical role in sterile compounding. Temperature control, air quality testing, and routine equipment inspections help maintain consistent preparation standards. The article notes that sterile compounded medications may undergo additional quality assurance checks before being dispensed to patients. These procedures help support both treatment effectiveness and patient safety.

The HelloNation article also explains that pharmacies performing sterile compounding are expected to follow USP guidelines established for sterile preparation. These USP guidelines outline requirements for cleanroom pharmacy operations, environmental testing, employee training, and quality assurance practices. The article emphasizes that maintaining compliance with USP guidelines helps reinforce contamination prevention and consistent preparation standards for compounded prescriptions.

Patients seeking sterile compounded medications may also look for pharmacies that participate in accreditation programs or are overseen by state boards. The article explains that these programs review safety procedures, documentation practices, and facility standards to help maintain medication safety. Regular environmental monitoring and staff competency evaluations are also identified as important safeguards in sterile compounding operations.

The article further explains that communication between pharmacists, healthcare providers, and patients remains an important part of safe compounded prescriptions. Compounding pharmacists review prescriptions carefully, confirm dosing instructions, and evaluate ingredient compatibility before preparation begins. This collaborative approach supports medication safety by reducing the risk of errors and ensuring treatments meet individual patient needs.

The article concludes that sterile compounding continues to play an important role in healthcare, particularly for patients requiring customized therapies that are unavailable through traditional manufacturing channels. Whether preparing IV medications, injectable therapies, or other sterile compounded medications, pharmacies rely on contamination prevention procedures and strict preparation standards to support patient care. The article notes that understanding how sterile compounding works can help patients feel more informed about the safety measures involved in preparing specialized medications.

What Sterile Compounding Means for Medication Safety features insights from Laura Temple, a compounding pharmacist expert at Laura’s Pharmacy in Azle, Texas, on HelloNation.

About HelloNation

HelloNation is America’s Good News Network, a premier media platform built on the idea that good news travels faster when real people tell real stories. Through its community-focused publications and innovative “edvertising” approach, HelloNation delivers content that informs, inspires, and spotlights the leaders making a meaningful impact in their communities.

View original content to download multimedia:https://www.prnewswire.com/news-releases/hellonation-article-highlights-sterile-compounding-and-medication-safety-with-insights-from-compounding-pharmacist-expert-laura-temple-302831275.html

SOURCE HelloNation

Continue Reading

Technology

CIOs Forced to Rethink Manual Compliance Processes as Regulatory Complexity Rises, Says Info-Tech Research Group

Published

on

By

Regulatory demands are increasing in volume, complexity, and speed, leaving many organizations reliant on fragmented, manual approaches that slow response times and increase risk. New insights from Info-Tech Research Group show that organizations need to adopt more structured and scalable approaches to keep pace with regulatory change. The firm’s recently published blueprint, Build a Regulatory IT Response Engine, provides frameworks, tools, and step-by-step guidance to help organizations translate regulatory requirements into actionable IT controls and prioritized initiatives.

ARLINGTON, Va., July 21, 2026 /PRNewswire/ — Growing regulatory pressure across jurisdictions is forcing organizations to rethink how they interpret, prioritize, and execute compliance requirements. Many IT teams continue to operate with inconsistent processes and limited coordination, resulting in delayed initiatives and increased exposure to financial and reputational risk. Info-Tech’s blueprint, Build a Regulatory IT Response Engine, introduces a coordinated and repeatable approach to help IT leaders operationalize compliance and improve execution outcomes.

Info-Tech’s findings indicate that while organizations recognize the need for faster and more consistent regulatory response, they continue to face barriers such as fragmented interpretation of requirements, weak prioritization, and limited scalability. AI-enabled tools can help streamline analysis and accelerate response planning, but without a coordinated approach grounded in governance and human oversight, those benefits are difficult to realize.

“Regulatory response is becoming too complex to manage through disconnected, manual processes,” says Ahmad Jowhar, senior research analyst at Info-Tech Research Group. “IT leaders need a repeatable way to interpret requirements, prioritize action, and use AI to accelerate planning without losing the governance and oversight needed to execute effectively.”

Key Challenges IT Leaders Face in Regulatory Response

Despite ongoing investments in compliance, organizations continue to face systemic challenges that hinder effective execution. Info-Tech’s blueprint highlights several areas where IT and compliance leaders struggle most:

Fragmented and manual processes that slow regulatory interpretation and response.Inconsistent application of regulatory requirements across teams and jurisdictions.Poor prioritization of IT initiatives, leading to missed deadlines and duplicated effort.Limited scalability to manage increasing regulatory volume and complexity.Misalignment between compliance activities and broader business priorities.

Info-Tech’s Framework for Building a Regulatory IT Response Engine

To address these challenges, Info-Tech recommends a structured, AI-enabled approach that improves consistency, speed, and scalability. The firm’s Build a Regulatory IT Response Engine blueprint outlines the following key priorities for IT leaders:

Define the regulatory landscape: Establish organizational context, governance structures, and a centralized inventory of applicable regulations.Translate requirements into IT controls: Use AI-enabled analysis and structured assessments to convert regulatory obligations into actionable controls.Prioritize IT initiatives: Align initiatives based on cost, effort, impact, and regulatory timelines to reduce execution risk.Build and communicate a roadmap: Develop a clear, resource-aligned roadmap to guide execution and stakeholder alignment.Establish a repeatable process: Continuously monitor, adapt, and refine regulatory response capabilities to maintain compliance over time.

Organizations that adopt this structured approach can move from reactive compliance efforts to a more proactive and scalable model that shortens response timelines, reduces manual effort, and strengthens execution.

The firm’s Build a Regulatory IT Response Engine blueprint includes practical tools such as a Regulation Inventory Tool, a Regulatory Response IT Action Plan Tool, a Communication Deck Template, and a Compliance Program Framework. By applying these resources, IT leaders can standardize regulatory responses, improve prioritization, and help ensure compliance initiatives are executed on time and in alignment with business priorities.

For exclusive and timely commentary from Info-Tech’s experts, including Ahmad Jowhar, and access to the complete Build a Regulatory IT Response Engine blueprint, please contact pr@infotech.com.

About Info-Tech Research Group

Info-Tech Research Group is the “get things done” partner for over 30,000 IT, HR, and marketing leaders worldwide. The fastest growing research and advisory firm, Info-Tech enables leaders to make well-informed decisions and transform their organizations through AI, strategic foresight, step-by-step methodologies, practical tools, industry-leading advisory, and training programs. For nearly 30 years, tens of thousands of private and public organizations have trusted Info-Tech to lead their most important initiatives through periods of change and deliver outcomes that truly matter.

To learn more about Info-Tech’s HR research and advisory services, visit McLean & Company, and for data-driven software buying insights and vendor evaluations, visit the firm’s SoftwareReviews platform.

Media professionals can register for unrestricted access to research across IT, HR, and software and hundreds of industry analysts through the firm’s Media Insiders program. To gain access, contact pr@infotech.com.

For information about Info-Tech Research Group or to access the latest research, visit infotech.com and connect via LinkedIn and X.

View original content to download multimedia:https://www.prnewswire.com/news-releases/cios-forced-to-rethink-manual-compliance-processes-as-regulatory-complexity-rises-says-info-tech-research-group-302831286.html

SOURCE Info-Tech Research Group

Continue Reading

Technology

Atomera to Announce Second Quarter 2026 Financial Results and Host Webinar on Tuesday, August 4, 2026

Published

on

By

LOS GATOS, Calif., July 21, 2026 /PRNewswire/ — Atomera Incorporated (NASDAQ: ATOM), a semiconductor materials and technology licensing company, announced today that it plans to release its second quarter 2026 financial results after the market closes on Tuesday, Aug. 4, 2026.

The company will host a live video Zoom webinar at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) on Tuesday, Aug. 4, 2026, to discuss the results. The live webinar can be accessed through Atomera’s investor relations website at https://ir.atomera.com. A replay of the webcast will be available for 12 months. To pre-register for the webinar, use the following link.

https://atomera.zoom.us/webinar/register/WN_OJFbTWe1SIyV69LLdDadCw

About Atomera

Atomera Incorporated is a semiconductor materials and technology licensing company focused on deploying its proprietary, silicon-proven technology into the semiconductor industry. Atomera has developed Mears Silicon Technology™ (MST®), which increases performance and power efficiency in semiconductor transistors. MST can be implemented using equipment already deployed in semiconductor manufacturing facilities and is complementary to other nano-scaling technologies already in the semiconductor industry roadmap.  More information can be found at www.atomera.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/atomera-to-announce-second-quarter-2026-financial-results-and-host-webinar-on-tuesday-august-4-2026-302830602.html

SOURCE Atomera Incorporated

Continue Reading

Trending